Tesaro, AnaptysBio collaborate on immune checkpoint inhibitors
This article was originally published in Scrip
Executive Summary
Cancer drug developer Tesaro entered the hot immuno-oncology space with an exclusive, worldwide license and collaboration agreement for antibodies from AnaptysBio that target three different immune checkpoint receptors.
You may also be interested in...
GSK Grows Immuno-Oncology Credentials With New Dostarlimab Indication
GlaxoSmithKline’s checkpoint inhibitor Jemperli has gained a second indication in the US, for the treatment of mismatch repair-deficient solid tumors, affirming the company’s drive to develop a new portfolio of cancer therapies.
Tesaro's Zejula Expansion Includes Keytruda Combo, Lung Cancer
The company, encouraged by positive Phase I data from a trial testing the PARP inhibitor niraparib in combination with Merck's PD-1 inhibitor Keytruda in recurrent ovarian cancer, plans to initiate a larger trial by the end of the year or early in 2018.
Lilly’s Latest Leadership Shuffle Gives CSO Skovronsky Immunology Oversight
Lilly Diabetes president Mike Mason is retiring, prompting a shifting of responsibilities among the executive team as the company gears up for key product approvals.